Oncimmune signs commercialisation partnership in Russia
The five-year initial term aims to generate revenues of at least £5 million.
Read More
Tag: Russia
- MHRA approves new treatment for severe alopecia areata
- Aplagon doses first patient in phase 2a trial of APAC
- NHS to offer fezolinetant for menopause‑related hot flushes and night‑sweats
- UCB reports superiority of bimekizumab in psoriatic arthritis study
- Kainova reports positive results for DT‑9081 in advanced solid tumours
